Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name FLT3 exon 14 ins FLT3 Y842D
Gene Variant Detail

FLT3 exon 14 ins (gain of function - predicted)

FLT3 Y842D (unknown)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Relevant Treatment Approaches Therapy Name Approval Status Evidence Type Efficacy Evidence References
FLT3 exon 14 ins FLT3 Y842D hematologic cancer resistant Sorafenib Preclinical - Cell culture Actionable In a preclinical study, transformed hematologic cells expressing FLT3-ITD with FLT3 Y842D were resistant to Nexavar (sorafenib) treatment in culture (PMID: 19318574). 19318574
FLT3 exon 14 ins FLT3 Y842D hematologic cancer resistant Quizartinib Preclinical - Cell culture Actionable In a preclinical study, FLT3 Y842D was identified as a secondary mutation in transformed hematologic cells expressing FLT3-ITD that acquired resistance to Vanflyta (quizartinib) in culture (PMID: 25487917). 25487917
FLT3 exon 14 ins FLT3 Y842D hematologic cancer sensitive Midostaurin Preclinical - Cell culture Actionable In a preclinical study, Rydapt (midostaurin) inhibited proliferation of transformed hematologic cells expressing FLT3-ITD with FLT3 Y842D in culture (PMID: 19318574). 19318574
FLT3 exon 14 ins FLT3 Y842D hematologic cancer sensitive Sunitinib Preclinical - Cell culture Actionable In a preclinical study, Sutent (sunitinib) inhibited proliferation of transformed hematologic cells expressing FLT3-ITD with FLT3 Y842D in culture (PMID: 19318574). 19318574